| |
| |
|
| Insider
Information: |
Foehr Matthew W |
| Relationship: |
President and CEO, Dir... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
3,948,737 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$33,186,682 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
3,948,737 |
|
|
| Total
Value |
$33,186,682 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
4
|
|
Stock
price went up :
|
6
|
0
|
| Stock
price went down : |
7
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
 32.7%
|
 -89.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
162,187 |
2011-04-18 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2022-05-02 |
111,250 |
2015-05-04 |
0 |
Premium* |
|
|
Qualigen Therapeutics Inc |
QLGN |
Director |
2020-04-10 |
138,635 |
2015-06-24 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
President and CEO, Dir... |
2024-05-24 |
3,536,665 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
136 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-05-10 |
4 |
S |
$167.63 |
$1,488,687 |
D/D |
(8,881) |
101,201 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-09-04 |
4 |
AS |
$255.01 |
$3,060,082 |
D/D |
(12,000) |
103,300 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-09-04 |
4 |
OE |
$9.97 |
$184,049 |
D/D |
13,044 |
115,300 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-10-01 |
4 |
AS |
$273.88 |
$3,286,560 |
D/D |
(12,000) |
105,388 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-10-01 |
4 |
OE |
$9.97 |
$194,457 |
D/D |
14,088 |
117,388 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2018-12-12 |
4 |
OE |
$9.97 |
$79,750 |
D/D |
7,999 |
113,387 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-01-23 |
4 |
D |
$111.78 |
$287,051 |
D/D |
(2,568) |
118,081 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
7,262 |
119,365 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,472 |
125,553 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-02-15 |
4 |
D |
$120.86 |
$341,550 |
D/D |
(2,826) |
122,727 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-03-14 |
4 |
OE |
$9.97 |
$148,493 |
D/D |
14,894 |
140,447 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-06-11 |
4 |
OE |
$21.92 |
$22,008 |
D/D |
1,004 |
141,451 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-08-12 |
4 |
OE |
$21.92 |
$25,493 |
D/D |
1,163 |
142,614 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-09-05 |
4 |
OE |
$21.92 |
$22,030 |
D/D |
1,005 |
143,619 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-11-12 |
4 |
OE |
$21.92 |
$21,942 |
D/D |
1,001 |
144,620 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-12-20 |
4 |
D |
$105.87 |
$386,849 |
D/D |
(3,654) |
148,337 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2019-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
7,371 |
149,781 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
7,396 |
156,229 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-13 |
4 |
OE |
$21.92 |
$10,872 |
D/D |
496 |
148,833 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-14 |
4 |
AS |
$95.84 |
$692,467 |
D/D |
(7,225) |
156,229 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-14 |
4 |
OE |
$14.47 |
$104,546 |
D/D |
7,225 |
163,454 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-15 |
4 |
D |
$97.23 |
$241,714 |
D/D |
(2,486) |
153,743 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-27 |
4 |
OE |
$14.47 |
$141,941 |
D/D |
8,931 |
155,449 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-02-27 |
4 |
AS |
$110.00 |
$794,750 |
D/D |
(7,225) |
153,743 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2020-03-13 |
4 |
OE |
$21.92 |
$43,840 |
D/D |
2,000 |
157,449 |
0 |
- |
|
136 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
